AOD-9604
Also known as: hGH Fragment 176-191, Advanced Obesity Drug
Modified hGH Fragment | Fat Loss Peptide
Overview
AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis without the side effects of full growth hormone. Unlike full GH, it does not increase IGF-1, affect glucose metabolism, or cause insulin resistance.
Key benefits
- Targets fat loss through selective lipolysis
- Avoids growth hormone side effects
- No effect on blood glucose or insulin
- Does not increase IGF-1 levels
- Metabolically safer than full hGH
- Emerging cartilage repair potential
Mechanism of action
Stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation, without binding to the GH receptor. Does not affect glucose metabolism or increase IGF-1 levels.
Molecular data
- Type
- Modified hGH C-terminal fragment
- Half-life
- 3-4 minutes
Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Indications
What the research community uses this compound for, with self-reported effectiveness.
Fat Loss
Joint Health
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 250-300mcg | Once daily (morning, fasted) | — |
| — | 400-500mcg | Once daily (morning, fasted) | — |
| — | 250mcg | Once daily | — |
| — | 200mcg | Once daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Generally well-tolerated in clinical trials
- Mild injection site reactions possible
- No reported effects on blood glucose or insulin
Contraindications
- Pregnancy or breastfeeding
- WADA prohibited - athletes subject to testing must avoid
Monitoring
- Injection site reactions
- Body composition changes
- General well-being
References
Primary literature and clinical-trial data informing this entry.